MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus

MLA

Peter M K de Blank, et al. “MEK Inhibitors for Neurofibromatosis Type 1 Manifestations: Clinical Evidence and Consensus.” Neuro-Oncology, vol. 24, no. 11, July 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....fdc09be891aa248dab39ba370d386094&authtype=sso&custid=ns315887.

APA

Peter M K de Blank, Andrea M Gross, Srivandana Akshintala, Jaishri O Blakeley, Gideon Bollag, Ashley Cannon, Eva Dombi, Jason Fangusaro, Bruce D Gelb, Darren Hargrave, AeRang Kim, Laura J Klesse, Mignon Loh, Staci Martin, Christopher Moertel, Roger Packer, Jonathan M Payne, Katherine A Rauen, Jonathan J Rios, … Michael J Fisher. (2023). MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus. Neuro-Oncology, 24(11).

Chicago

Peter M K de Blank, Andrea M Gross, Srivandana Akshintala, Jaishri O Blakeley, Gideon Bollag, Ashley Cannon, Eva Dombi, et al. 2023. “MEK Inhibitors for Neurofibromatosis Type 1 Manifestations: Clinical Evidence and Consensus.” Neuro-Oncology 24 (11). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....fdc09be891aa248dab39ba370d386094&authtype=sso&custid=ns315887.